J. Martin Carroll's most recent trade in Esperion Therapeutics Inc. was a trade of 44,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Esperion Therapeutics Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 33,000 | 97,650 (0%) | 0% | 0 | Common Stock | |
| Catalent Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Oct 2024 | 4,663 | 32,734 (0%) | 0% | 0 | Common Stock | |
| Esperion Therapeutics Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 32,500 | 32,500 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 23,000 | 64,650 (0%) | 0% | 0 | Common Stock | |
| Catalent Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2023 | 6,993 | 28,071 (0%) | 0% | 0 | Common Stock | |
| Catalent Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2023 | 555 | 21,078 (0%) | 0% | 0 | Common Stock | |
| Esperion Therapeutics Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 5,150 | 41,650 (0%) | 0% | 0 | Common Stock | |
| Esperion Therapeutics Inc. | J. Martin Carroll | Director | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 10 May 2023 | 23,091 | 36,500 (0%) | 0% | 1.6 | 36,285 | Common Stock |
| Esperion Therapeutics Inc. | J. Martin Carroll | Director | Purchase of securities on an exchange or from another person at price $ 1.49 per share. | 10 May 2023 | 8,409 | 13,409 (0%) | 0% | 1.5 | 12,545 | Common Stock |
| Catalent Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 4,149 | 20,523 (0%) | 0% | 0 | Common Stock | |
| Esperion Therapeutics Inc. | J. Martin Carroll | Director | Purchase of securities on an exchange or from another person at price $ 5.64 per share. | 02 Jun 2022 | 5,000 | 5,000 (0%) | 0% | 5.6 | 28,180 | Common Stock |
| Esperion Therapeutics Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Catalent Inc. | J. Martin Carroll | Director | Other type of transaction at price $ 134.12 per share. | 29 Nov 2021 | 3,136 | 11,663 (0%) | 0% | 134.1 | 420,600 | Common Stock |
| Catalent Inc. | J. Martin Carroll | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Nov 2021 | 3,136 | 16,374 (0%) | 0% | 0 | Common Stock | |
| Catalent Inc. | J. Martin Carroll | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Nov 2021 | 3,136 | 3,136 (0%) | 0% | 0 | Common Stock | |
| Catalent Inc. | J. Martin Carroll | Director | Other type of transaction at price $ 134.12 per share. | 29 Nov 2021 | 3,136 | 0 (0%) | 0% | 134.1 | 420,600 | Common Stock |
| Catalent Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 1,402 | 19,510 (0%) | 0% | 0 | Common Stock | |
| TherapeuticsMD Inc | J. Martin Carroll | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 96,864 | 0 | - | - | Restricted Stock Units | |
| TherapeuticsMD Inc | J. Martin Carroll | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2021 | 96,864 | 106,864 (0%) | 0% | - | Common Stock | |
| TherapeuticsMD Inc | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 99,174 | 99,174 | - | - | Restricted Stock Units | |
| Catalent Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Oct 2020 | 2,125 | 18,108 (0%) | 0% | 0 | Common Stock | |
| Catalent Inc. | J. Martin Carroll | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Aug 2020 | 661 | 15,983 (0%) | 0% | 0 | Common Stock |